伴PLZF/RARα阳性急性早幼粒细胞白血病的治疗:附1例报告并文献复习  

Combination of arsenic trioxide and chemotherapy in the treatment of PLZF/RARα positive acute promyelocytic leukemia patient: a case report and literature review

作　　者：刘凯奇[1] 刘兵城[1] 周春林 秘营昌[1] 魏述宁[1] 张广吉[1] 王建祥[1] 

机构地区：[1]中国医学科学院,北京协和医学院血液学研究所血液病医院,天津300020

出　　处：《临床血液学杂志》2012年第6期719-721,共3页Journal of Clinical Hematology

基　　金：国家科技重大专项课题(No:20112X09302-007-04);卫生行业专项项目(No:201202017)

摘　　要：目的:提高对伴PLZF/RARα融合基因阳性的急性早幼粒细胞白血病(APL)诊断和治疗的认识。方法:报道1例伴PLZF/RARα融合基因阳性APL的诊断、治疗经过及随访情况。结果:患者经骨髓形态学、组织化学、免疫分型、染色体、融合基因等检查确诊为APL伴PLZF/RARα融合基因阳性,予以三氧化二砷(ATO)联合化疗达到完全缓解(CR)后,继续予以ATO联合化疗强化巩固治疗。随访11个月,患者仍处于CR1期。结论:伴PLZF/RARα融合基因阳性APL可采用ATO联合化疗诱导、巩固治疗,延长患者生存时间。Objective：To improve the diagnosis and therapy of acute promyelocytic leukemia（ APL） with posi- tive PLZF/RARa fusion gene. Method：We reviewed the patient＇s clinical features,laboratory results,treatment and following up. Result：This patient was diagnosed APL with PLZF/RARaa（＋）by morphologic,immunophenotypic, histochemistry,genetic and molecular studies. Complete hematologic remission was obtained after induction chemo- therapy which used arsenic trioxide （ATO） with combined chemotherapy. Until now, the patient was still in CR1. Conclusion：The patient with PLZF/RARaa（＋） can achieve CR and prolong the survival time through ATO with combined chemotherapy.

关 键 词：白血病 早幼粒细胞性 急性 三氧化二砷 化疗 PLZF RARα 

分 类 号：R733.71[医药卫生—肿瘤]